A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Innovative Medical

Status and phase: Completed; Phase 4

Conditions: Glaucoma

Treatments: Drug: Bimatoprost

Study type: Interventional

Funder types: Industry

Identifiers

NCT00348062

5177

Details and patient eligibility

About

Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• · Male or female > 18 years of age

  • No prior use of bimatoprost
  • Diagnosis of open-angle glaucoma or ocular hypertension
  • Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

• · Known contraindication to bimatoprost

  • Uncontrolled systemic disease
  • Active ocular disease other than glaucoma or ocular hypertension
  • Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
  • History of intraocular surgery within the last 3 months